Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical 07/11/2022 — Expected to
July 11, 2022
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical 07/11/2022 — Expected to
DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A Mark your calendar – DOSED
Ritual drug use during Inca human sacrifices on Ampato mountain (Peru): Results of a toxicological
Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Protestors of psilocybin ban arrested at DEA headquarters At least 17 activists were arrested for
ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From
If you’ve been wanting to try psychedelic therapy legally, now’s your chance! Johns Hopkins is
A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological
Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder Wesana Health (WESA)
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application NAPLES,
Wellbeing Digital Sciences’ Subsidiary KGK Science Engaged by Lophos Pharmaceuticals for Novel Peyote Study Peyote
Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety Novamind (NM) announced that
Tasmanian ketamine study to treat chronic pain patients About 60% of patients with chronic pain
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality
Incannex executes license agreement with Monash University to develop a combination treatment using virtual reality
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program Tripping on ibogaine can last over
XPhyto provides progress update on Psychedelic Medicine Programs and Novel Compounds Milestone Vancouver, Canada, and
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the